These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36705285)

  • 1. Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement.
    Peasah SK; Huang Y; Palli SR; Swart EC; Donato BM; Pimple P; Bovier J; Manolis C; Good CB
    J Manag Care Spec Pharm; 2023 Feb; 29(2):152-160. PubMed ID: 36705285
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a U.S. Commercially Insured and Medicare Advantage Population.
    Chung H; Deshpande G; Zolotarjova J; Quimbo RA; Kern DM; Cochetti PT; Willey VJ
    J Manag Care Spec Pharm; 2019 May; 25(5):612-620. PubMed ID: 31039058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
    Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
    J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
    Raju A; Shetty S; Cai B; D'Souza AO
    J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Patient Migration Patterns and Related Health Care Costs Within a National Medicare Advantage Prescription Drug Plan After Implementation of an Oxycodone HCl Extended-Release Access Restriction.
    Chen CC; De AP; Sweet B; Wade RL
    J Manag Care Spec Pharm; 2017 Aug; 23(8):902-912. PubMed ID: 28737985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
    Garry EM; Schneeweiss S; Eapen S; Petruski-Ivleva N; Cheever E; Murk W; Rajan A; Rassen JA; Gambino D; Jang H; Rubin E; Jan S
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1442-1452. PubMed ID: 31778623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
    Raju A; Pimple P; Stafkey-Mailey D; Farrelly E; Shetty S
    Diabetes Ther; 2022 Jan; 13(1):25-42. PubMed ID: 34727356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic assessment of changes to an existing medication therapy management program of a large regional health plan.
    Peasah SK; Hammonds T; Liu Y; Campbell V; Manolis C; Good CB
    J Manag Care Spec Pharm; 2021 Feb; 27(2):147-156. PubMed ID: 33506728
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS; Fu H; Taylor AD; Kwan AY
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
    J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.